Key Takeaways
Oorja Bio launched with $30 million in Series A financing to advance a novel peptide therapeutic for idiopathic pulmonary fibrosis (IPF), entering a market dominated by two aging blockbusters. The funding from Westlake BioPartners will move its lead candidate, ORJ-001, into a Phase 2 clinical trial this year after receiving IND clearance from the U.S. Food and Drug Administration.
“Our team is energized to deliver on our goal of redefining the future of fibrotic diseases, beginning with ORJ-001,” said Sujay Kango, Chief Executive Officer at Oorja Bio. “ORJ-001 was designed with this biology in mind and may provide, for the first time, a therapeutic intervention that repairs and reverses fibrosis and promotes disease modification.”
Oorja’s ORJ-001 is a first-in-class peptide that targets the underlying pathology of IPF by restoring the function of alveolar epithelial type 2 (AEC2) cells. This mechanism differs from the standard-of-care antifibrotic therapies, pirfenidone (Esbriet) from Roche’s Genentech and nintedanib (Ofev) from Boehringer Ingelheim, which slow disease progression but do not halt or reverse lung damage. The IPF market, valued at approximately $2.97 billion in 2025, is projected to grow to $6.73 billion by 2035, according to a ResearchAndMarkets.com report.
The Houston-based company is betting that its approach can capture a significant share of this expanding market by offering more than just symptom management. The challenge is steep, as the IPF space is littered with failed late-stage trials, including those for ziritaxestat and pamrevlumab. However, recent positive data from United Therapeutics’ TETON-1 trial for inhaled treprostinil (Tyvaso), which showed a significant reduction in lung function decline, has renewed optimism in the field. Oorja’s leadership, including CEO Sujay Kango and CMO Janethe Pena, previously led the successful development of sotatercept at Acceleron Pharma, adding a layer of clinical and regulatory experience that could prove critical.
This article is for informational purposes only and does not constitute investment advice.
